US FDA suspends COVID-19 vaccine clinical research Novavax Pharmaceuticals (NVAX.US) once fell nearly 30% before the market

The Zhitong Finance App noticed that before the US stock market on Wednesday, the stock price of Novavax Pharmaceuticals (NVAX.US) once fell nearly 30%. Previously, the US FDA suspended its new drug application for COVID-19 and influenza combination vaccines and independent influenza vaccine candidates on the grounds that a trial participant had serious adverse events. As of press release, Novavax Pharmaceuticals fell 16.83% to $10.61.

“The clinical suspension was due to a CIC phase 2 trial participant from outside the US who was vaccinated in January 2023 who spontaneously reported a serious adverse event of motor neuropathy,” the FDA said.

The trial was completed in July 2023, and participants had adverse events in September 2024.

Novavax Chief Medical Officer Robert Walker said, “We are working closely with the FDA to provide the necessary information to better understand this observation and address clinical issues.”

The company said previous COVID-19 and influenza trials showed no signs of motor neuropathy, and clinical holds will not affect its independent COVID-19 vaccine research new drug application.